Article
Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation - 1 Dec 2011
Gijsen Violette, Mital Seema, van Schaik Ron H, Soldin Offie P, Soldin Steven J, van der Heiden Ilse P, Nulman Irena, Koren Gideon, de Wildt Saskia N
Abstract excerpt
BACKGROUND: Tacrolimus is one of the commonly used immunosuppressive drugs for pediatric heart transplants. Large variation exists in pharmacokinetics during the direct post-transplant period, resulting in an increased risk of adverse events. Limited data are available on the interaction of age,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.